Ravulizumab Receives Accelerated Approval by FDA to Reduce Proteinuria in IgAN

The FDA granted accelerated approval to ravulizumab in the United States for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression, marking it as the first and only C5 complement inhibitor for this condition.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 22 Oct 2026 and 2 Nov 2026.